Hutchison China MediTech Limited (HCM) Social Stream
HUTCHMED (CHINA) LTD (HCM) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering HCM.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-09-20 | 3 | $52 | $40.3 | $47.575 | $16.61 | 186.42% |
| 2022-03-10 | 4 | $52 | $46.25 | $49.062 | $16.61 | 195.38% |
| 2022-03-16 | 4 | $52 | $30.35 | $45.087 | $16.61 | 171.44% |
| 2022-05-02 | 4 | $50 | $22 | $36.837 | $16.61 | 121.78% |
| 2022-06-08 | 5 | $50 | $22 | $36.837 | $16.61 | 121.78% |
| 2022-08-02 | 5 | $50 | $20.25 | $34.312 | $16.61 | 106.57% |
| 2022-08-08 | 6 | $50 | $14 | $30.25 | $16.61 | 82.12% |
| 2022-08-13 | 6 | $50 | $16 | $30.65 | $16.61 | 84.53% |
| 2022-11-14 | 6 | $50 | $16 | $31.24 | $16.61 | 88.08% |
| 2022-12-15 | 6 | $50 | $16 | $29.366 | $16.61 | 76.8% |
| 2023-01-26 | 5 | $50 | $16 | $29.7 | $16.61 | 78.81% |
| 2023-02-08 | 4 | $50 | $16 | $29.7 | $16.61 | 78.81% |
| 2023-03-08 | 6 | $50 | $16 | $29.866 | $16.61 | 79.81% |
| 2023-04-25 | 6 | $50 | $16 | $29.333 | $16.61 | 76.6% |
| 2023-06-06 | 5 | $50 | $16 | $31.2 | $16.61 | 87.84% |
| 2023-08-01 | 5 | $50 | $14.6 | $30.72 | $16.61 | 84.95% |
| 2023-08-04 | 6 | $50 | $14.6 | $30.92 | $16.61 | 86.15% |
| 2023-08-21 | 5 | $50 | $14.6 | $34.65 | $16.61 | 108.61% |
| 2023-11-10 | 6 | $50 | $14.6 | $34.65 | $16.61 | 108.61% |
| 2023-11-16 | 6 | $45 | $14.6 | $26.4 | $16.61 | 58.94% |
| 2023-11-24 | 7 | $45 | $14.6 | $25.54 | $16.61 | 53.76% |
The Trend in the Analyst Price Target
Over the past 37 months, HCM's average price target has gone down $12.52.
HCM reports an average of 93.5% for its upside potential over the past 44 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-01-26 | 4 | 50 | 16.0 | 29.700 | 19.83 | 49.77% |
| 2023-03-08 | 5 | 50 | 16.0 | 29.866 | 13.57 | 120.09% |
| 2023-06-06 | 5 | 50 | 16.0 | 31.200 | 12.60 | 147.62% |
| 2023-08-21 | 6 | 50 | 14.6 | 34.650 | 13.50 | 156.67% |
| 2023-11-10 | 6 | 50 | 14.6 | 34.650 | 19.02 | 82.18% |
HCM Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.57 | 5 | 0 | 2 | 0 | 0 | 7 |
The Trend in the Broker Recommendations
Over the past 45 months, HCM's average broker recommendation rating worsened by 0.27.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for HCM as an investment opportunity.
- To contextualize these metrics, consider that out of all US stocks, HUTCHMED (CHINA) LTD's variance in analysts' estimates is lower than -2164.56% of them.
- HCM has a greater upside potential (average analyst target price relative to current price) than 2180.67% of all US stocks.
- HUTCHMED (CHINA) LTD's number of analysts covering the stock is higher than 621.99% of all US stocks.
- In the context of stocks in the mid market cap category, HUTCHMED (CHINA) LTD's average analyst price target is higher than 1296.67% of them.
Stocks similar to HUTCHMED (CHINA) LTD in the Pharmaceutical Products industry regarding analyst recommendations and price targets are ORGO, ANAB, and PTGX.
View All Top Stocks by Price Target
Make investment decisions regarding HCM using the data that counts. Try POWR Ratings for free.